By Bio-IT World Staff
September 3, 2012 | The bioinformatics firm CLC bio has acquired fellow Danish company Molegro, a drug discovery software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
The acquisition of Molegro supports CLC bio's strategy of expanding their bioinformatics offerings beyond next-generation sequencing, as well as in bioinformatics areas considered of value to their customers. Financial terms of the transaction were not disclosed.
“We have always had a strong focus on the science behind our software, and joining CLC bio allows us to become part of a strong analysis platform and focus even more on developing the next generation of molecular docking products,” said Molegro founder and CEO, René Thomsen.
“CLC bio has demonstrated the capability to build an elaborate analysis platform and distribute it internationally, and exactly that competence is the best way to take the features of Molegro’s software to the next level.”
“Since 2005, Molegro has demonstrated the ability to develop and support superior molecular docking products. We look forward to adding the very talented people from Molegro to our team at CLC bio,” said CLC bio CEO Thomas Knudsen. “This acquisition underlines our dedication to always look for the most viable ways to enhance our analysis platform for the benefit of our customers.”
CLC bio says it plans to invest significant resources into the continued development of the acquired data modeling and molecular docking software. Molegro will immediately become part of CLC bio's organization at the company’s headquarters in Aarhus, Denmark.